We are live on ! Find out more
NPCE icon

Neuropace
NPCE

25 hedge funds and large institutions have $176M invested in Neuropace in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

124% more capital invested

Capital invested by funds: $78.6M → $176M (+$97.3M)

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

14% more funds holding

Funds holding: 22 → 25 (+3)

1.01% more ownership

Funds ownership: 68.88% → 69.89% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
25
Holders Change
+3
Holders Change %
+13.64%
% of All Funds
0.4%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
10
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$4.66M
2
KLC
Kent Lake Capital
Nevada
+$2.49M
3
EI
EAM Investors
California
+$829K
4
Morgan Stanley
Morgan Stanley
New York
+$239K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$227K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.03M
2
Millennium Management
Millennium Management
New York
-$2.6M
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.97K
4
Wells Fargo
Wells Fargo
California
-$872
5
TRCT
Tower Research Capital (TRC)
New York
-$404
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
– -$404 -90 Closed
1
2

NPCE Hedge Fund Activity: Q3 2023 in Review

25 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q3 2023, worth a combined $176M — up 124% from $78.6M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NPCE positions and 1 closed out — a net gain of 4 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $4.66M. The largest seller was Fidelity Investments, cutting an estimated $3.03M.

  • 25 institutional investors held Neuropace (NPCE) as of Q3 2023, up from 22 in Q2 2023.
  • Funds reported $176M of Neuropace stock for Q3 2023, up 124% quarter-over-quarter.
  • 5 funds opened new Neuropace positions in Q3 2023 and 1 closed out, a net change of +4 holders.
  • The largest Neuropace buyer in Q3 2023 was Nantahala Capital Management, an estimated $4.66M added.
  • The largest Neuropace seller in Q3 2023 was Fidelity Investments, an estimated $3.03M sold.

Based on aggregated 13F filings for Q3 2023.